Loading
A phase 1 trial of MOMA-313 run by MOMA Therapeutics, now recruiting.
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06545942 by MOMA Therapeutics, with 220 participants planned, started 2024-08-13. Conditions recorded: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer and Homologous Recombination Deficiency. Interventions recorded: MOMA-313 and Olaparib.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Breast cancer (all types), Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/